Koers Oxford BioMedica plc London S.E.
Aandelen
GB0006648157_GB
GB0006648157
Biotechnologie & Medisch Onderzoek
Omzet 2023 | 89,54 mln. 112 mln. 105 mln. | Omzet 2024 * | 130 mln. 162 mln. 152 mln. | Marktkapitalisatie | 277 mln. 345 mln. 323 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | -157 mln. -196 mln. -183 mln. | Nettowinst (verlies) 2024 * | -35 mln. -43,72 mln. -40,91 mln. | EV/omzet 2023 | 2,38 x |
Nettoliquiditeiten 2023 * | 49,23 mln. 61,49 mln. 57,53 mln. | Nettoliquiditeiten 2024 * | 13,8 mln. 17,24 mln. 16,13 mln. | EV/omzet 2024 * | 2,02 x |
K/w-verhouding 2023 |
-1,35
x | K/w-verhouding 2024 * |
-8,09
x | Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 80,81% |
Recentste transcriptie over Oxford BioMedica plc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Frank Mathias
CEO | Chief Executive Officer | 62 | 27-03-23 |
Stuart Paynter
DFI | Director of Finance/CFO | 52 | 29-08-17 |
Chairman | 68 | 24-06-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Leone Patterson
BRD | Director/Board Member | 61 | 01-05-23 |
Chairman | 68 | 24-06-20 | |
Stuart Henderson
BRD | Director/Board Member | 66 | 01-06-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,06% | 102 mld. | |
+1,56% | 96,09 mld. | |
+2,13% | 22,28 mld. | |
-17,12% | 21,4 mld. | |
-8,82% | 18,14 mld. | |
-39,98% | 17,02 mld. | |
-14,20% | 16,09 mld. | |
+7,64% | 13,83 mld. | |
+33,28% | 11,97 mld. |